Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trialPepijn Eijsvogel, Jean‐Cosme Dodart, Marieke L. de Kam et al.|Nature Medicine|2024Cited by 38
Precise disease heterogeneity and progression quantification in MSA and Parkinson’s disease using machine learningRobel K Gebre, Prashanthi Vemuri, P. A. Low et al.|Scientific Reports|2026Cited by 0